UNITED THERAPEUTICS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 275 USD | -0.51% |
|
-0.05% | +25.06% |
| Jun. 03 | Liquidia's Yutrepia Launch Cleared as Court Denies Injunction | MT |
| May. 16 | United Therapeutics Insider Sold Shares Worth $545,800, According to a Recent SEC Filing | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With a P/E ratio at 11.24 for the current year and 10.32 for next year, earnings multiples are highly attractive compared with competitors.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's enterprise value to sales, at 3.66 times its current sales, is high.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +25.06% | 12.2B | B+ | ||
| +51.85% | 57.87B | B- | ||
| +41.42% | 40.25B | A | ||
| -5.25% | 39.94B | B | ||
| -5.16% | 28.54B | C | ||
| +12.79% | 26.4B | B- | ||
| -20.18% | 19.33B | B | ||
| +30.88% | 12.4B | C+ | ||
| +0.61% | 12.23B | B+ | ||
| -9.14% | 11.06B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- UTHR Stock
- Ratings United Therapeutics Corporation
